- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04439695
Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
A Phase 1, Observer-blinded, Randomized, Placebo-controlled, Parallel Group Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Subjects will be screened up to 14 days (Day -14 to Day 0) before randomization.
On the planned day of vaccination (Day 1), subjects will be randomized in a 1:1:1:1 ratio (N = 30 subjects/group) to receive study vaccine or placebo by intramuscular (IM) injection.
Approximately 5 subjects per group (N = 20) will be enrolled in parallel initially, and safety data through Day 8 will be collected. An Independent Data Monitoring Committee (IDMC) will convene to review Day 8 safety data before any additional subjects will be enrolled. If there are no safety concerns in the IDMC meeting, study enrollment will continue.
Blood and serum samples for safety laboratory tests and HAI titers will be obtained at baseline on Day 1 before administration of vaccine dose and after vaccination.
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Omaha, Nebraska, United States, 68134
- Meridian Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria
- Have read, understood, and signed the informed consent form (ICF)
- Healthy adult males and females ages 18 to 49 years, inclusive at screening
- Body mass index (BMI) of ≥18 and ≤34 kg/m2 at screening
- Must be in general good health before study participation with no clinically relevant abnormalities that could interfere with study assessments
- Women of childbearing potential (WOCBP) and men whose sexual partners are WOCBP must be able and willing to use at least 1 highly effective method of contraception during the study and for 3 months after the study completion. A female subject is considered to be a WOCBP after menarche and until she is in a postmenopausal state for 12 consecutive months (without an alternative medical cause) or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).
- Female subjects of childbearing potential must have a negative urine pregnancy test before vaccination
- Must be able to attend all visits for the duration of the study and comply with all study procedures, including completion of Diary Card according to the study schedule.
Exclusion Criteria
- History of an acute or chronic medical condition that, in the opinion of the investigator, would render vaccination unsafe or would interfere with the evaluation of responses.
- History of ongoing clinical condition or medication or treatments that may adversely affect the immune system.
- Individuals with any elevated (Grade 2 or higher) laboratory test assessed as clinically significant by investigator at screening
Individuals with any elevated (Grade 2 or higher) liver function enzyme at screening, regardless of the appraisal of clinical significance (cannot be retested to qualify for study). See below the criteria for excluding subjects with elevated liver enzymes:
- Alanine aminotransferase (ALT)/aspartate aminotransferase (AST): >3 × upper limit of normal (ULN)
- Total bilirubin: >2 × ULN
- Alkaline phosphatase (ALP)/gamma-glutamyl transferase (GGT): >2.5 × ULN
- Active neoplastic disease (excluding nonmelanoma skin cancer that was successfully treated) or a history of any hematological malignancy. For this criterion, "active" is defined as having received treatment within the past 5 years.
- Long-term (greater than 2 weeks) use of oral or parenteral steroids or high-dose inhaled steroids (>800 μg/day of beclomethasone dipropionate or equivalent) within 6 months before screening (nasal and topical steroids are allowed)
- History of autoimmune or inflammatory disease
- Women currently pregnant, nursing, or planning a pregnancy between enrollment and 181 days after randomization
- History of a previous serious adverse reaction to any influenza vaccine
- History of Guillain-Barré Syndrome
- History of anaphylactic-type reaction to injected vaccines
- Known or suspected hypersensitivity to 1 or more of the components of TAP-V001
- History of illicit drug use or alcohol abuse in the year before screening
- Receipt of any influenza vaccine within 6 months before screening
- Receipt of any vaccine within 1 month before screening
- Acute illness or fever within 3 days before study enrollment (enrollment may be delayed for full recovery if acceptable to the investigator)
- Individuals currently participating or planning to participate in a study that involves an experimental agent (vaccine, drug, biologic, device, or medication); or who have received an experimental agent within 1 month before enrollment in this study; or who expect to receive another experimental agent during participation in this study; or who intend to donate blood during the study period.
- Receipt of immunoglobulin or another blood product within the 3 months before enrollment in this study or those who expect to receive immunoglobulin or another blood product during this study.
- Individuals who plan to receive another vaccine, including seasonal influenza vaccine, during the entire 6-month study period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Low Dose KBP-V001
Subjects in this group will receive the low dose of KBP-V001.
|
Low dose of KBP-V001
|
Experimental: Intermediate KBP-V001
Subjects in this group will receive the intermediate dose of KBP-V001.
|
Intermediate dose of KBP-V001
|
Experimental: High Dose KBP-V001
Subjects in this group will receive the high dose of KBP-V001.
|
High dose of KBP-V001
|
Placebo Comparator: Placebo
Subjects in this group will receive placebo
|
Buffered Saline Solution
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Solicited administration site reactions
Time Frame: 7 days after vaccination
|
Occurrences of Adverse Events
|
7 days after vaccination
|
Solicited systemic events
Time Frame: 7 days after vaccination
|
Occurrences of Adverse Events
|
7 days after vaccination
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of Unsolicited Adverse Events
Time Frame: 43 days after vaccination
|
Safety Endpoint
|
43 days after vaccination
|
Number of Serious Adverse Events and Medically Attended Events
Time Frame: 181 days after vaccination
|
Safety Endpoint
|
181 days after vaccination
|
Vaccine HAI antibody Titers
Time Frame: Day 1, 29, 43, 181
|
Vaccine HAI antibody Titers for each treatment group
|
Day 1, 29, 43, 181
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brandon Essink, MD, Meridian Clinical Research
- Study Director: Hugh Haydon, Kentucky BioProcessing
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- KBP-101
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Influenza
-
Novartis VaccinesCompletedInfluenza | Seasonal Influenza | Human Influenza | Influenza Due to Unspecified Influenza VirusBelgium
-
Gamaleya Research Institute of Epidemiology and...CompletedInfluenza A | Influenza A Virus Infection | Influenza Epidemic | Influenza H5N1Russian Federation
-
Vanderbilt University Medical CenterHuman Vaccines ProjectCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Influenza Type B | Influenza A H3N2 | Influenza A H1N1United States
-
NPO PetrovaxCompletedVaccine Reaction | Influenza | Influenza, Human | Influenza A | Acute Respiratory Infection | Influenza Type B | Flu | Influenza A H3N2 | Influenza A H1N1 | Flu, Human | Influenza EpidemicRussian Federation
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Avian Influenza | H1N1 InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...University of Oxford; Wellcome Trust; World Health OrganizationCompletedInfluenza | Avian Influenza | Severe InfluenzaSingapore, Thailand, Vietnam
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...Completed
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza Immunisation | Avian InfluenzaUnited States
-
National Institute of Allergy and Infectious Diseases...CompletedInfluenza | Influenza Immunisation | Avian InfluenzaUnited States
Clinical Trials on Low dose
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)RecruitingRecurrent Mantle Cell Lymphoma | Refractory Mantle Cell LymphomaUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedPneumonia | Coronavirus Infection in 2019 (COVID-19) | Severe Acute Respiratory Syndrome (SARS) PneumoniaUnited States
-
MedImmune LLCCompletedNon-alcoholic Fatty Liver Disease (NAFLD) | Non-alcoholic Steatohepatitis (NASH)United States, Puerto Rico
-
Beijing Northland Biotech. Co., Ltd.CompletedSafety and Efficacy Study of Thymosin Beta 4 in Patients With Acute Myocardial Infarction.InfarctionAcute Myocardial InfarctionChina
-
Lucozade Ribena SuntoryKing's College LondonCompletedPostprandial PeriodUnited Kingdom
-
Indonesia UniversityMedika Natura Sdn BhdCompleted
-
Postgraduate Institute of Medical Education and...Completed
-
Yiling Pharmaceutical Inc.CompletedPharmacokinetics | Healthy Adult Subjects | Safety and TolerabilityUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)RecruitingLung CarcinomaUnited States
-
CalciMedica, Inc.CompletedSystemic Inflammatory Response Syndrome | Acute PancreatitisUnited States